Tucatinib, Trastuzumab, and Capecitabine for Leptomeningeal Metastases in Breast Tumors
Erica Stringer-Reasor, MD, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.
Erica Stringer-Reasor, MD, an assistant professor of medicine at the University of Alabama at Birmingham, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.
Transcript:
0:07 | Leptomeningeal metastasis is a rare but aggressive form of breast cancer with very limited treatment options. There are not many randomized studies or single arm studies evaluating this purely due to the rareness of this disease.
0:24: | We definitely know that as we treat patients with her to targeted therapies, it will treat their body systemically. But eventually they will help a CNS relapse, and we thought it would be important to investigate this and a small cohort of patients and a combination that was recently approved by the FDA for metastatic breast cancer, as well as specifically patients diagnosed for brain metastases. Again, this combination has not been evaluated in left on meninggeal disease.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
